CN109689055A - 用于治疗非精神分裂症患者中的阴性症状的组合物和方法 - Google Patents

用于治疗非精神分裂症患者中的阴性症状的组合物和方法 Download PDF

Info

Publication number
CN109689055A
CN109689055A CN201780045461.2A CN201780045461A CN109689055A CN 109689055 A CN109689055 A CN 109689055A CN 201780045461 A CN201780045461 A CN 201780045461A CN 109689055 A CN109689055 A CN 109689055A
Authority
CN
China
Prior art keywords
compound
subject
weeks
composition
negative symptoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780045461.2A
Other languages
English (en)
Chinese (zh)
Inventor
R.鲁斯林格
M.达维德森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Priority to CN202111014262.XA priority Critical patent/CN113694065A/zh
Priority to CN202111014298.8A priority patent/CN113908156A/zh
Publication of CN109689055A publication Critical patent/CN109689055A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201780045461.2A 2016-05-25 2017-05-23 用于治疗非精神分裂症患者中的阴性症状的组合物和方法 Pending CN109689055A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202111014262.XA CN113694065A (zh) 2016-05-25 2017-05-23 用于治疗非精神分裂症患者中的阴性症状的组合物和方法
CN202111014298.8A CN113908156A (zh) 2016-05-25 2017-05-23 用于治疗非精神分裂症患者中的阴性症状的组合物和方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662341590P 2016-05-25 2016-05-25
US62/341590 2016-05-25
PCT/US2017/034030 WO2017205393A1 (en) 2016-05-25 2017-05-23 Compositions and methods for treating negative symptoms in non-schizophrenic patients

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202111014262.XA Division CN113694065A (zh) 2016-05-25 2017-05-23 用于治疗非精神分裂症患者中的阴性症状的组合物和方法
CN202111014298.8A Division CN113908156A (zh) 2016-05-25 2017-05-23 用于治疗非精神分裂症患者中的阴性症状的组合物和方法

Publications (1)

Publication Number Publication Date
CN109689055A true CN109689055A (zh) 2019-04-26

Family

ID=58794265

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201780045461.2A Pending CN109689055A (zh) 2016-05-25 2017-05-23 用于治疗非精神分裂症患者中的阴性症状的组合物和方法
CN202111014262.XA Pending CN113694065A (zh) 2016-05-25 2017-05-23 用于治疗非精神分裂症患者中的阴性症状的组合物和方法
CN202111014298.8A Pending CN113908156A (zh) 2016-05-25 2017-05-23 用于治疗非精神分裂症患者中的阴性症状的组合物和方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202111014262.XA Pending CN113694065A (zh) 2016-05-25 2017-05-23 用于治疗非精神分裂症患者中的阴性症状的组合物和方法
CN202111014298.8A Pending CN113908156A (zh) 2016-05-25 2017-05-23 用于治疗非精神分裂症患者中的阴性症状的组合物和方法

Country Status (9)

Country Link
US (2) US20190216793A1 (https=)
EP (1) EP3463356A1 (https=)
JP (3) JP2019516756A (https=)
KR (2) KR20240005110A (https=)
CN (3) CN109689055A (https=)
PH (1) PH12018502445A1 (https=)
SG (2) SG11201810358YA (https=)
TW (2) TWI820001B (https=)
WO (1) WO2017205393A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116847843A (zh) * 2021-02-09 2023-10-03 泽农医药公司 用于治疗快感缺乏的电压门控的钾通道开放剂

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2910528T3 (es) 2014-12-02 2022-05-12 Minerva Neurosciences Inc Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil)piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia
IL308650B2 (en) 2017-06-21 2025-08-01 Minerva Neurosciences Inc Gastro-resistant controlled release oral dosage forms
KR102886241B1 (ko) * 2018-08-21 2025-11-14 미쓰비시 타나베 파마 코퍼레이션 음성 증상 및 장애를 치료하고, 신경가소성을 증가시키고, 신경보호를 촉진시키기 위한 롤루페리돈의 용도
TWI879755B (zh) * 2020-02-20 2025-04-11 日商田邊三菱製藥股份有限公司 魯哌啶酮用於治療負性症狀及疾病、增加神經可塑性及促進神經保護的用途
KR102360137B1 (ko) * 2020-03-25 2022-02-08 주식회사 케이티앤지 카트리지 및 이를 포함하는 에어로졸 생성 장치
US20240212824A1 (en) * 2022-12-21 2024-06-27 Woebot Labs, Inc. Administering a digital therapeutic using a device interface to treat anxiety or depression

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1426405A (zh) * 2000-02-29 2003-06-25 三菱制药株式会社 新型环状酰胺衍生物
CN103220910A (zh) * 2010-07-20 2013-07-24 昔勒尼药品公司 使用环酰胺衍生物治疗精神分裂症的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200616608A (en) * 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
US20090088449A1 (en) * 2006-02-07 2009-04-02 Mitsubishi Tanabe Pharma Corporation 4-acylaminopyridine derivative mediated neurogenesis
KR20080089279A (ko) * 2007-03-30 2008-10-06 미쓰비시 타나베 파마 코퍼레이션 우울증의 예방 및/또는 치료제
CN103108548A (zh) * 2010-07-20 2013-05-15 昔勒尼药品公司 使用环酰胺衍生物治疗σ受体介导的病症的方法
US8937900B2 (en) * 2010-07-20 2015-01-20 Qualcomm Incorporated Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies
US9737531B2 (en) * 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
EP3144308B1 (en) * 2014-05-16 2020-06-24 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
ES2910528T3 (es) * 2014-12-02 2022-05-12 Minerva Neurosciences Inc Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil)piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1426405A (zh) * 2000-02-29 2003-06-25 三菱制药株式会社 新型环状酰胺衍生物
CN103220910A (zh) * 2010-07-20 2013-07-24 昔勒尼药品公司 使用环酰胺衍生物治疗精神分裂症的方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116847843A (zh) * 2021-02-09 2023-10-03 泽农医药公司 用于治疗快感缺乏的电压门控的钾通道开放剂

Also Published As

Publication number Publication date
US20230190726A1 (en) 2023-06-22
TWI851224B (zh) 2024-08-01
PH12018502445A1 (en) 2019-09-09
WO2017205393A1 (en) 2017-11-30
CN113908156A (zh) 2022-01-11
TWI820001B (zh) 2023-11-01
TW202335672A (zh) 2023-09-16
JP2019516756A (ja) 2019-06-20
KR20190013846A (ko) 2019-02-11
US20190216793A1 (en) 2019-07-18
SG11201810358YA (en) 2018-12-28
JP2022188185A (ja) 2022-12-20
SG10202011470UA (en) 2021-01-28
JP2025000921A (ja) 2025-01-07
TW201808288A (zh) 2018-03-16
CN113694065A (zh) 2021-11-26
EP3463356A1 (en) 2019-04-10
KR20240005110A (ko) 2024-01-11

Similar Documents

Publication Publication Date Title
US11680044B2 (en) Pharmaceutical composition comprising 5-methoxy-n,n-dimethyltryptamine
CN109689055A (zh) 用于治疗非精神分裂症患者中的阴性症状的组合物和方法
US20230023092A1 (en) Treatment of depression and other various disorders with psilocybin
JP6166739B2 (ja) 女性性的機能不全の治療における薬学的製剤およびその使用方法
US20250000881A1 (en) Treatment of treatment resistant depression with psilocybin
KR20250005173A (ko) 산후 우울증의 치료
JP2022526101A (ja) 重水素化デキストロメトルファン及びキニジンを使用して統合失調症の陰性症状を治療する方法
ES2967484T3 (es) Tratamiento de los síntomas inducidos por el ciclo menstrual
KR20230016636A (ko) 알츠하이머병과 관련된 불안을 치료하는 방법
KR20240122455A (ko) 치료-저항성 우울증의 치료에서 사용하기 위한 실로사이빈 및 보조적 세로토닌 재흡수 저해제
CN109640990A (zh) 用于治疗焦虑症的(2S)-1-[4-(3,4-二氯苯基)哌啶-1-基]-3-[2-(5-甲基-1,3,4-噁二唑-2-基)苯并[b]呋喃-4-基氧基]丙-2-醇或其代谢物
WO2026068950A1 (en) Pharmaceutical compositions of 5-meo-dmt for use in the treatment of alcohol use disorders
EA049139B1 (ru) Лечение симптомов, вызванных менструальным циклом
CN118488843A (zh) 用赛洛西宾治疗难治性抑郁症
KR20250138805A (ko) 정신 장애의 치료
HK40068314A (en) Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
Morgan et al. Clinical Social Work and
Morgan et al. Emphasis on Indigenous Medicine in a Latino Community

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20190426

RJ01 Rejection of invention patent application after publication